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Abstract
Background: parkin mutations are a common cause of parkinsonism. Possessing two parkin
mutations leads to early-onset parkinsonism, while having one mutation may predispose to late-
onset disease. This dosage pattern suggests that some parkin  families should exhibit
intergenerational variation in age at onset resembling anticipation. A subset of familial PD exhibits
anticipation, the cause of which is unknown. The aim of this study was to determine if anticipation
was due to parkin mutation dosage.
Methods: We studied 19 kindreds that had early-onset parkinsonism in the offspring generation,
late-onset parkinsonism in the parent generation, and ≥ 20 years of anticipation. We also studied
28 early-onset parkinsonism cases without anticipation. Patients were diagnosed by neurologists at
a movement disorder clinic. parkin analysis included sequencing and dosage analysis of all 12 exons.
Results: Only one of 19 cases had compound parkin mutations, but contrary to our postulate, the
affected relative with late-onset parkinsonism did not have a parkin mutation. In effect, none of the
anticipation cases could be attributed to parkin. In contrast, 21% of early-onset parkinsonism
patients without anticipation had parkin mutations.
Conclusion: Anticipation is not linked to parkin, and may signify a distinct disease entity.
Background
Mutations in the parkin gene are a common cause of par-
kinsonism. parkin was originally discovered as the cause
of autosomal recessive juvenile parkinsonism [1]. How-
ever, recent reports suggest that not all parkin mutations
are recessive [2-5], nor is age at onset always early [6-9].
Several studies have found heterozygous mutations in
patients with late onset parkinsonism, suggesting that a
single parkin mutation predisposes to later disease onset
[8-10]. Collectively, these reports imply that parkin may
exert a dosage effect in which possession of two mutations
(homozygous or compound heterozygous) leads to early-
onset parkinsonism, while possession of one normal and
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one mutant parkin (heterozygous) increases the risk for
late-onset parkinsonism.
Several groups have reported what appears to be genetic
anticipation in parkinsonism [11-13]. In the kindreds
studied by them, the parent generation had typical late-
onset parkinsonism and the individuals in the offspring
generation developed the disease at much earlier ages.
Barring the possibility that this pattern is an artifact of
ascertainment bias (which cannot be ruled out until a bio-
logical mechanism is found), the intergenerational differ-
ence in onset age may be indicative of one of several
mechanisms. The most common cause of anticipation is
triplet repeat expansions. In a few parkinsonism families,
disease has been shown to segregate with pathogenic
expansions in SCA loci, but the search for other expansion
loci in familial parkinsonism has been unsuccessful [14-
16]. Other mechanisms that could result in anticipation
include: change in mitochondrial heteroplasmy, which
can affect disease severity and age at onset; a modifier
gene that segregates independently of the disease gene;
and parent/child exposure to a toxin. Gene dosage for
dominant mutations can also mimic anticipation. For
example, Familial Hypercholestrolemia is an autosomal
dominant disorder in which heterozygotes develop the
disease after the 4th decade of life, whereas homozygotes
show symptoms at much younger ages, sometimes at
birth (OMIM *143890).
Is anticipation in parkinsonism related to parkin mutation
dosage? We hypothesized that some parkin mutations are
dominant: heterozygotes have incomplete penetrance and
may develop late-onset parkinsonism, whereas homozy-
gotes and compound heterozygotes have accelerated dis-
ease leading to early-onset parkinsonism. This unifying
hypothesis was attractive because if true, it could explain
the reported variations in mode of inheritance of parkin
(recessive in some families, dominant in others), the
range in age at onset from juvenile to late onset, and the
significantly earlier onset in some of the children of
affected parents. To test this hypothesis, we studied parkin
in 19 kindreds with early-onset parkinsonism in the index
generation, late-onset parkinsonism in the parent genera-
tion, and exhibited ≥ 20 years of anticipation.
Methods
Families were recruited from a movement disorder clinic.
The probands and affected family members had the clini-
cal diagnosis of idiopathic Parkinson's disease (here
referred to as parkinsonism due to lack of autopsy confir-
mation). Diagnosis was made by a neurologist according
to the British Parkinson's Disease Brain Bank criteria
except that family history was not an exclusion criterion
[17]. These families were identified through an index case
(a clinic patient) who reported a family history of parkin-
sonism. Positive family history was defined as patient
reporting a first or second degree relative with parkinson-
ism, although we did inquire about more distant relatives
as well. Clinic patients were enrolled sequentially and
their affected relatives were subsequently identified and
enrolled. For affected relatives we obtained medical
records or personally examined them when possible. In
some families the index case had early onset and the rela-
tive had late onset, in others, the index case had late onset
and the relative with early onset was subsequently identi-
fied. The study was approved by the Institutional Review
Boards at the participating institutions.
DNA was extracted from blood using standard protocol.
Genotyping was blind to phenotype. To identify point
mutations, we sequenced both DNA strands of all 12
exons. Exons and 50–100 bp of flanking intronic
sequences were PCR-amplified [1], agarose gel-purified
(Gene-clean III, Bio101), and directly sequenced by dye-
terminator cycle sequencing (ABI, Big-Dye) using an
ABI377 sequencer. To identify exon deletions and dupli-
cations, we analyzed gene dosage using real-time fluores-
cence-based PCR (ABI 7700 Sequence Detector).
Amplification of subject genomic DNA was performed
using fluorescently labeled probes (5' FAM or VIC, 3'
TAMRA) and Taqman Universal PCR Mix (ABI) [4,18].
parkin exon amplifications were multiplexed under stand-
ard conditions with an 84-bp fragment of a single-copy
human  β-actin gene (Genbank accession number
XM_004814) as an internal control. A standard curve was
generated for each parkin exon and for β-actin using 0, 5,
15, 55 and 220 ng of control human genomic DNA. The
number of PCR cycles required before the ABI 7700
detects each parkin exon product (CT value) was plotted
against the corresponding exon standard curve, thus cal-
culating the relative parkin  copy number. The copy
number for each exon was normalized to the single-copy
actin gene within each multiplexed reaction and to a nor-
mal control reference individual, allowing an estimate of
the number of copies of parkin. Optimal threshold levels
for each primer set were maintained between plate analy-
ses. All samples were analyzed in triplicate.
Results
Nineteen kindreds were chosen for parkin analysis based
on having parkinsonism in two consecutive generations,
late-onset parkinsonism in the parent generation (onset
ages 59 to 89 years, mean 71.0 ± 8.5), early-onset parkin-
sonism in the offspring generation (onset ages 8 to 47
years, mean 37.2 ± 9.8), and ≥ 20 years of anticipation as
measured by the difference in mean ages at onset in two
generations. In the younger generation, 2 probands had
onset before age 20, 1 was in his twenties, and 16 were
over 30 years old. It was hypothesized that the affected
individuals with early-onset parkinsonism areBMC Neurology 2005, 5:4 http://www.biomedcentral.com/1471-2377/5/4
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homozygous or compound heterozygous, and the parents
and other relatives with late-onset parkinsonism are het-
erozygous. For parkin analysis, we began with the family
member from the generation with the earlier onset, so as
to enrich for parkin mutations. We expected the majority
of the index cases to be compound heterozygous. At the
minimum, 16–49% of index cases should have had muta-
tions, since this is the range reported for early-onset spo-
radic and familial parkinsonism [7,9,19]. However, only
one case had parkin  mutations. This patient had com-
pound deletions in exon 3 with onset at age 8. Her sister,
onset at age 15, also had the compound mutation. The rel-
ative with late-onset was an uncle with onset age of 64.
Contrary to our hypothesis, the uncle did not have a par-
kin mutation. The cause of late-onset parkinsonism in the
uncle was different from the nieces. In effect, we did not
find any cases where we could attribute the intergenera-
tional difference in age at onset to parkin dosage.
We also analyzed parkin in 28 additional patients with
early-onset parkinsonism (onset age 14 to 40 years, mean
32.8 ± 7.0), either with (n = 4) or without (n = 24) family
history, but with no evidence of anticipation. In this
group, 3 probands had onset at or before age 20, 5 were in
their twenties, and 20 were over 30 years old. Nine muta-
tions were found in six individuals. Two subjects were
compound heterozygous (onset ages 31 and 37) and four
were heterozygous (onset ages 14, 25, 37, 37). The fre-
quency of parkin  carriers in early-onset parkinsonism
without anticipation was 21% which is in the range 16%
– 49% reported in the literature (the lower range repre-
sents population and clinic based studies similar to ours,
while the higher frequencies were found in highly selected
autosomal recessive families). It was of interest to deter-
mine if any of the parents of the three early-onset parkin-
sonism patients with compound mutations had
developed late-onset parkinsonism. All six parents were
heterozygous (5 were confirmed by genotyping, one was
inferred), and all had remained free of parkinsonism to
the ages of 53, 60, 63, 74, 76 and 78 yrs. These individuals
may still develop parkinsonism.
Discussion
Familial parkinsonism with anticipation may be more
common than classical dominant and recessive subtypes
combined. In our clinic population, among 487 patients
studied, 145 had a first or second degree relative with PD;
that is 30% which is in line with the published figures for
other referral clinics. Among the 145 familial cases, 110
had parkinsonism in consecutive generations, which is
compatible with autosomal dominant inheritance, and
35 had an affected sibling or cousin, which is suggestive of
recessive inheritance. However, among the 110, only 26
were compatible with a classical dominant pattern (i.e.,
<10 years intergenerational variation in onset); while 63
exhibited 10–68 years of anticipation, and 7 had 10–17
years of reverse anticipation (14/110 had unknown onset
ages). Our clinic is a referral center, which explains the rel-
atively high proportions of early-onset and familial cases.
The interesting finding was the relative proportions of
autosomal dominant, autosomal recessive and anticipa-
tion cases within the familial subtype. Despite its rela-
tively high prevalence, at least in our clinic, familial
parkinsonism with anticipation has been largely over-
looked in genetic research. A few parkinsonism families
have been attributed to expansions in known SCA loci,
but in the majority of the kindreds, the cause remains
unknown. The more obvious possibilities are mitochon-
drial inheritance, modifier genes, parent-child exposure to
environmental triggers, as yet unidentified triplet repeats
or dominant genes with dosage effect, and in some cases,
artifactual appearance of anticipation due to ascertain-
ment bias. None of these are mutually exclusive; more
than one may be true and operative in different families.
The current parkin literature suggest that possessing two
parkin  mutations is fully penetrant and leads to early-
onset parkinsonism, whereas having only one mutation
may be incompletely penetrant and lead to later disease
onset. While the causative link to early-onset parkinson-
ism is widely accepted, the association of parkin with late-
onset parkinsonism remains controversial [9,10,20,21].
We postulated that, if parkin heterozygotes are at risk for
late-onset disease, then some parkin  families should
exhibit intergenerational variation in age at onset resem-
bling anticipation, where heterozygous parents develop
late-onset parkinsonism and children who inherit two
mutations develop early-onset parkinsonism. We hoped
to explain the appearance of anticipation in relation to
parkin dosage, but the findings do not support this postu-
late. While the results rule out a link between parkin and
anticipation in these families, they do not negate the asso-
ciation of parkin with late-onset parkinsonism.
Conclusion
The phenomenon of anticipation is not due to parkin
mutation dosage. The underlying mechanism for antici-
pation may be genetic or environmental. Identification
and a-priori classification of pedigrees that exhibit signif-
icant intergenerational age at onset variation, as being dis-
tinct from families that display classical dominant
pattern, may facilitate gene mapping studies by reducing
heterogeneity. Anticipation in parkinsonism merits inves-
tigation in its own right, not only because it is a common
phenomenon and may account for a large subset of famil-
ial parkinsonism, but it may also uncover a novel mecha-
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